TEVA Fair Value Estimate
$21.9838.5% overvalued
Blended fair value estimate based on DCF, Graham Number, and earnings-based models.
Teva- Pharmaceutical Industries Ltd
Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products.
Current Price
$35.73
-0.78%GoodMoat Value
$21.98
38.5% overvaluedProfile
Valuation (TTM)
Market Cap$41.08B
P/E26.27
EV—
P/B5.19
Shares Out1.15B
P/Sales2.37
Revenue$17.35B
EV/EBITDA16.43
Teva- Pharmaceutical Industries Ltd (TEVA) Valuation
TEVA Valuation Metrics
FCF$1.15B
FCF Growth Rate31.40%
EPS Growth (CAGR)50.00%
WACC10.00%
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →TEVA Valuation & Fair Value Analysis
Teva- Pharmaceutical Industries Ltd (TEVA) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The GoodMoat Fair Value target for Teva- Pharmaceutical Industries Ltd is $21.98. The current stock price is $35.73, suggesting the stock is 62.6% overvalued.
The price-to-earnings (P/E) ratio is 26.27. Price-to-book ratio is 5.19. Price-to-sales ratio is 2.37. Enterprise value to EBITDA is 16.43. PEG ratio is 0.38.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Teva- Pharmaceutical Industries Ltd's intrinsic value.